| Trial ID # | NCT05123482 |
| Phase | I/IIa |
| Drug Class | Antibody Drug Conjugates: B7H4 |
| Drug Name | Puxitatug samrotecan |
| Alternate Drug Names | AZD8205 |
| Drugs in Trial | Puxitatug samrotecan |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 47 patients in dose escation, median 5 prior therapies (2-9); 17 OC |
| Therapy Setting | Recurrence |
| Efficacy | ORR: 17.6% (3PR) |
| Conclusion | Puxitatug samrotecan (AZD8205) has a manageable safety profile consistent with other Topoisomerase 1 inhibitor ADCs and shows preliminary efficacy in heavily pretreated patients with prior progression on standard treatment |
| Reference | Meric-Bernstam F et al. Initial results from a first-in-human study of the B7-H4- directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors. Ann Oncol (2024) 35 (2) abstract 606O |